Serum anti-nucleocapsid antibody level induced after primary infection is an immunological surrogate of protection against SARS-CoV-2 re-infection in hybrid immunity holders

Sho Miyamoto,Koki Numakura,Ryo Kinoshita,Takeshi Arashiro,Hiromizu Takahashi,Hiromi Hibino,Minako Hayakawa,Takayuki Kanno,Akiko Sataka,Akira Ainai,Satoru Arai,Motoi Suzuki,Daisuke Yoneoka,Takaji Wakita,Tadaki Suzuki

DOI: https://doi.org/10.1101/2024.06.05.24308479

2024-06-06

Abstract:Background In 2024, there was quite high seroprevalence of anti-spike (S) protein antibodies against SARS-CoV-2 in Japanese adults, owing to the high vaccination coverage by spike-based vaccines. Nevertheless, the COVID-19 epidemic continues, albeit with low rates of severe illness, and hybrid immunity holders are becoming more common in these populations. It is necessary to determine the immunological protection correlates against SARS-CoV-2 re-infection in individuals with hybrid immunity because the currently available immune correlates were established by analyzing individuals possessing vaccine-induced immunity only. Methods We conducted an ad hoc prospective cohort study to measure serum anti-SARS-CoV-2 antibody levels in 4,496 Japanese adults as part of the national COVID-19 seroepidemiological survey. This ad hoc study evaluated the correlation between anti-S and anti-nucleocapsid (N) antibody levels at the first visit and their effectiveness in infection prevention until the second visit, including undiagnosed re-infections during the Omicron BA.5 epidemic period from December 2022 to March 2023. Findings We assessed the combined effect of anti-N and anti-S antibody levels and found that the reduced infection risk associated with anti-S antibody levels was limited. Contrastingly, higher levels of anti-N antibodies were strongly linked to a reduced infection risk in the entire cohort and in individuals with hybrid immunity. Interpretation We demonstrate a high correlation between reduced re-infection risk in hybrid immunity holders and high serum anti-N antibody levels, highlighting its potential as an immunological surrogate of protection against SARS-CoV-2 re-infection. The findings indicate that individuals with hybrid immunity are protected by a distinct form of immunity, beyond the presence of serum anti-S antibodies, which correlates with serum anti-N antibody levels. Funding The national COVID-19 seroepidemiological survey as a public health investigation was funded by the Ministry of Health, Labour and Welfare of Japan (MHLW). The ad hoc study based on the survey data as a research activity was funded by the Japan Agency for Medical Research and Development (AMED).

What problem does this paper attempt to address?

The paper discusses the immune protection correlates against SARS-CoV-2 reinfection in the population with mixed immunity (both vaccinated and naturally infected). The study found a stronger correlation between the antibody levels against nucleocapsid protein (N protein) and reduced risk of reinfection, compared to the antibody levels against spike protein (S protein). This indicates that anti-N protein antibodies may serve as immunological surrogate markers for assessing the protective immunity against SARS-CoV-2 reinfection. The study also emphasizes the importance of understanding the immune protection factors against reinfection (particularly the immunity associated with anti-N protein antibody levels) in the context of high vaccination coverage. This has implications for the development of more effective next-generation COVID-19 vaccines.